Use of Acetyl-L-Carnitine in Gerontological Practice

Пономарева, Е. В.

doi:10.1007/s11055-019-00754-8

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ALC exhibits a variety of physiological activities, including nutritional effects, neuroprotective effects, analgesic effects of the peripheral nervous system, antioxidant effects, and plays important roles in the functioning of male reproductive system. Commercially, ALC‐based drugs are mainly used to improve male fertility, treat Alzheimer’s disease, hepatic encephalopathy, depression, and diabetic peripheral neuropathy (Anikin, Makhova, & Shikh, 2019; Di Stefano, Di Lionardo, Galosi, Truini, & Cruccu, 2019; Gamidov, Ovchinnikov, & Popova, 2019; Jeong et al, 2017; Ponomareva, 2017; Rolim, da Silva, Flumignan, Abreu, & Dib, 2019).…”

Section: Introductionmentioning

confidence: 99%

A UPLC–MS/MS method for determination of endogenous l‐carnitine and acetyl‐l‐carnitine in serum of patients with depression

Nie

Liang

Shan

et al. 2020

Biomedical Chromatography

View full text Add to dashboard Cite

A simple, rapid, and selective ultra‐performance liquid chromatography–tandem mass spectrometry method for determination of l‐carnitine (LC) and acetyl‐l‐carnitine (ALC) in human serum was developed. Acetyl‐l‐carnitine‐d3 (ALC‐d3) was selected as internal standard (IS). After protein precipitation with acetonitrile–water (1 mL, 2:1, v/v), the analytes and IS were separated on a 2.5‐μm XSelect HSS T3 C18 column by gradient elution with methanol–water (containing 0.01% ammonia water) as the mobile phase at a flow rate of 0.2 mL/min. Analytes were detected with multiple reaction monitoring using a positive scan mode with electrospray ionization. Good linearity (R2 > 0.999) was observed in the concentration range for LC and ALC. The inter‐ and intra‐day values of relative error were −10.4% to 10.0% with CVs less than 9.84%. The average recoveries of the two analytes were 91.29%–98.23%. Blood samples containing LC and ALC were stable under various storage conditions. Normal, haemolytic, and hyperlipidaemic serum had no significant effect on the quantification of LC and ALC. This method was successfully applied to study the concentrations of endogenous LC and ALC in the serum of patients with first‐episode depression.

show abstract

Section: Introductionmentioning

confidence: 99%

A UPLC–MS/MS method for determination of endogenous l‐carnitine and acetyl‐l‐carnitine in serum of patients with depression

Nie

Liang

Shan

et al. 2020

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

Neuropharmacology in Alzheimer and Huntington Disease

Gupta

Rohatgi

2022

Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition)

View full text Add to dashboard Cite

The Alzheimer’s disease and Huntington’s disease are the two important neurodegenerative disorders currently under research for various therapeutic approaches ranging from newer biochemical molecules, plant extracts and food supplements to highly advanced biotechnological and genetic therapies. Alzheimer’s disease (AD), one of the leading causes of disability in the elderly population is exponentially rising worldwide. The acetylcholinesterase inhibitors and memantine, the mainstay of treatment only slow down the disease progression and provide symptomatic improvement. The cholinesterase inhibitors, rivastigmine and donepezil apart from improving cognition also delay hospitalization and reduce behavioural and psychological symptoms of dementia. Other cholinesterase inhibitors and cholinomimetic targets like muscarinic and nicotinic receptor agonists are in development. Extensive research in this area in the past few decades has given insight into the cellular and molecular pathogenesis of the disease. This has led to the development of certain novel strategies to modify the disease progression and prognosis. This includes amyloid and tau-based therapeutics, various immunotherapies, vaccines and food and plant supplements. Other new promising agents under research are anti-inflammatory drugs, neurotrophic factors and antioxidants. Huntington’s disease is a rare inherited neurodegenerative disorder producing motor, cognitive and psychiatric symptoms. A greater understanding of the pathology in the recent past has led to research into the development of newer therapeutic agents mainly DNA and RNA based therapies and technologies using gene editing tools. Several of these putative drugs are in preclinical studies and many of them have failed to show positive results. In this section, we are going to discuss the approved therapies for AD and HD currently in use, the status and evidence regarding drugs in various stages of clinical trial and mention advanced biotechnological and gene therapies under investigation.

show abstract

Use of Acetyl-L-Carnitine in Gerontological Practice

Cited by 2 publications

References 40 publications

A UPLC–MS/MS method for determination of endogenous l‐carnitine and acetyl‐l‐carnitine in serum of patients with depression

A UPLC–MS/MS method for determination of endogenous l‐carnitine and acetyl‐l‐carnitine in serum of patients with depression

Neuropharmacology in Alzheimer and Huntington Disease

Contact Info

Product

Resources

About